Manesh R. Patel, MD

Panelists discuss how chronic kidney disease (CKD) and uncontrolled hypertension create a damaging cycle, in which hypertension accelerates kidney damage while declining kidney function makes blood pressure harder to control.

Panelists discuss how evaluating uncontrolled hypertension in patients with early kidney dysfunction requires a careful investigation of underlying causes, including medication adherence, lifestyle factors, and potential secondary hypertension.

Panelists discuss how proper blood pressure measurement techniques require careful attention to patient positioning, cuff size selection, and standardized procedures to ensure accurate readings.

A panelist discusses how hypertensive disorders during pregnancy remain a leading cause of maternal mortality worldwide, affecting 5-10% of pregnancies and requiring careful monitoring, early detection, and appropriate medical management to protect both mother and baby.

Panelists discuss how the PRECISION trial evaluated aprocitentan, a dual endothelin receptor antagonist (ERA), in patients with resistant hypertension taking 3 antihypertensive medications including a diuretic.

Panelists discuss how the endothelin pathway critically regulates blood pressure and vascular health through the interplay between vasodilators and vasoconstrictors such as endothelin-1, representing a key mechanism in hypertension pathophysiology.

Panelists discuss how resistant hypertension management requires a structured approach combining lifestyle modifications, optimal doses of multiple drug classes, and the identification of underlying causes such as sleep apnea.

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Panelists discuss how traditional antihypertensive medications face challenges including adverse reactions, complex dosing regimens, and variable efficacy across different patient populations, which can limit their therapeutic success.

Panelists discuss how poor medication adherence and comorbidities such as chronic kidney disease (CKD) contribute to uncontrolled hypertension despite the availability of numerous treatment options, highlighting key challenges in achieving effective blood pressure management.

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients

Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.

Expert cardiologists discuss if there is such a thing as an LDL that is a too low.

Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.

Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.

Marc P. Bonaca, MD, MPH, of the University of Colorado School of Medicine, comments on the potential to personalize treatment with emerging therapies in the pipeline to better manage patients at high risk for cardiovascular disease in the future.

Unmet needs in the management of coronary artery disease and peripheral artery disease, and advice for working with patients and other healthcare professionals to optimize care for patients at high risk for cardiovascular disease.

Drs Marc P. Bonaca and Manesh R. Patel discuss the rationale for individualized treatment plans for patients with type 2 diabetes at high risk for cardiovascular disease.

Implications for treating patients at risk of cardiovascular disease with rivaroxaban plus aspirin based on the COMPASS and VOYAGER PAD clinical trials.

Recommendations for treating patients with coronary artery disease and type 2 diabetes with dual antiplatelet therapy based on data revealed by the THEMIS trial.

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Drs Marc P. Bonaca and Manesh R. Patel discuss the link between type 2 diabetes and cardiovascular disease along with risk factors that may lead to cardiovascular events.